Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpha/beta T-cell and CD19 B-cell depleted allogeneic stem cell transplantation followed by innate donor lymphocyte infusion in high-risk or relapsed acute leukemia/MDS
NL-OMON28903Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Jan 2011
- Modality
- Small Molecules, Peptides, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of innate donor lymphocyte infusion, zoledronic acid and cyclosporine in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS), sponsored by University Medical Center Utrecht. Primary endpoints: Time to neutrophil engraftment, Time to platelet engraftment and 7 more. Started Jan 2011; status: active, not recruiting.
02
Drugs
innate donor lymphocyte infusionzoledronic acidcyclosporine
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON28903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28903.